nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

24.07.2019

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

verfasst von: Federico Gatto, Claudia Campana, Francesco Cocchiara, Giuliana Corica, Manuela Albertelli, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Massimo Giusti, Diego Ferone

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion from a somatotroph pituitary adenoma. GH hypersecretion leads to overproduction of insulin-like growth factor-1 (IGF-1), which contributes to the somatic overgrowth, physical disfigurement, onset of multiple systemic comorbidities, reduced quality of life (QoL) and premature mortality of uncontrolled patients. Somatostatin receptor ligands, dopamine agonists and a GH receptor antagonist are currently available for medical therapy of acromegaly. The main aim of treatment is biochemical normalisation, defined as age-normalised serum IGF-1 values and random GH levels <1.0 μg/L. However, there is an increasing evidence suggesting that achieving biochemical control does not always decrease the burden of disease-related comorbidities and/or improve patients’ QoL. This lack of correlation between biochemical and clinical control can be due to both disease duration (late diagnosis) or to the peculiarity of a given comorbidity. Herein we conducted ad hoc literature searches in order to find the most recent and relevant reports on biochemical and clinical disease control during medical treatment of acromegaly. Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.

Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–73. https://doi.org/10.1056/NEJMra062453.CrossRefPubMed

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51. https://doi.org/10.1210/jc.2014-2700.CrossRefPubMed

Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52. https://doi.org/10.1210/er.2002-0022.CrossRefPubMed

Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95. https://doi.org/10.1530/EJE-08-0267.CrossRefPubMed

Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20(5):489–98. https://doi.org/10.1007/s11102-017-0838-2.CrossRefPubMedPubMedCentral

Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448–57. https://doi.org/10.1007/s11102-016-0725-2.CrossRefPubMedPubMedCentral

Lotti F, Rochira V, Pivonello R, Santi D, Galdiero M, Maseroli E, et al. Erectile dysfunction is common among men with acromegaly and is associated with morbidities related to the disease. J Sex Med. 2015;12(5):1184–93. https://doi.org/10.1111/jsm.12859.CrossRefPubMed

Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8. https://doi.org/10.1038/nrendo.2014.21.CrossRefPubMed

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61. https://doi.org/10.1038/s41574-018-0058-5.CrossRefPubMedPubMedCentral

10.

Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8(4):e61523. https://doi.org/10.1371/journal.pone.0061523.CrossRefPubMedPubMedCentral

11.

Bacigaluppi S, Gatto F, Anania P, Bragazzi NL, Rossi DC, Benvegnu G, et al. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. Endocrine. 2016;51(3):524–33. https://doi.org/10.1007/s12020-015-0619-5.CrossRefPubMed

12.

McKeage K. Pasireotide in acromegaly: a review. Drugs. 2015;75(9):1039–48. https://doi.org/10.1007/s40265-015-0413-y.CrossRefPubMed

13.

Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–33. https://doi.org/10.1210/jc.2013-3757.CrossRefPubMedPubMedCentral

14.

Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary. 2017;20(1):33–45. https://doi.org/10.1007/s11102-017-0792-z.CrossRefPubMed

15.

Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93(4):1324–30. https://doi.org/10.1210/jc.2007-2104.CrossRefPubMed

16.

Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur J Endocrinol. 2013;168(1):39–47. https://doi.org/10.1530/EJE-12-0602.CrossRefPubMed

17.

Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormon IGF Res. 2008;18(5):389–93. https://doi.org/10.1016/j.ghir.2008.02.001.CrossRef

18.

Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523–7. https://doi.org/10.1210/jc.2008-1371.CrossRefPubMed

19.

Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C et al. Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Front Endocrinol (Lausanne). 2017;8:40. https://doi.org/10.3389/fendo.2017.00040.

20.

Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667–74. https://doi.org/10.1210/jc.2003-031199.CrossRefPubMed

21.

Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol. 2017;176(5):645–55. https://doi.org/10.1530/EJE-16-1064.CrossRefPubMed

22.

Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al. Pegvisomant in acromegaly: an update. J Endocrinol Investig. 2017;40(6):577–89. https://doi.org/10.1007/s40618-017-0614-1.CrossRef

23.

Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol. 2007;67(1):65–70. https://doi.org/10.1111/j.1365-2265.2007.02836.x.CrossRef

24.

Christiansen Arlien-Soborg M, Trolle C, Alvarson E, Baek A, Dal J. Otto Lunde Jorgensen J. biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine. 2017;56(3):589–94. https://doi.org/10.1007/s12020-017-1258-9.CrossRefPubMed

25.

Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol. 2004;61(1):138–44. https://doi.org/10.1111/j.1365-2265.2004.02064.x.CrossRef

26.

Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–73. https://doi.org/10.1210/jc.2005-0260.CrossRefPubMed

27.

Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235–47. https://doi.org/10.1007/s11102-015-0684-z.CrossRefPubMed

28.

Puig DM. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol. 2015;83(1):3–14. https://doi.org/10.1111/cen.12731.CrossRef

29.

Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996;81(6):2356–62. https://doi.org/10.1210/jcem.81.6.8964877.CrossRefPubMed

30.

Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary. 2004;7(3):139–44. https://doi.org/10.1007/s11102-005-1756-2.CrossRefPubMed

31.

de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol. 2005;153(1):67–71. https://doi.org/10.1530/eje.1.01935.CrossRefPubMed

32.

Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormon IGF Res. 2005;15(3):200–6. https://doi.org/10.1016/j.ghir.2005.02.007.CrossRef

33.

Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol. 2005;62(3):282–8. https://doi.org/10.1111/j.1365-2265.2004.02191.x.CrossRef

34.

Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, et al. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res. 2008;40(6):422–6. https://doi.org/10.1055/s-2008-1065339.CrossRefPubMed

35.

Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35. https://doi.org/10.1210/jc.2010-2443.CrossRefPubMed

36.

Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–8. https://doi.org/10.1210/jcem.83.2.4556.CrossRefPubMed

37.

Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7. https://doi.org/10.1056/NEJM200004203421604.CrossRefPubMed

38.

van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–9.CrossRefPubMed

39.

Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9. https://doi.org/10.1210/jc.2013-2480.CrossRefPubMedPubMedCentral

40.

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84. https://doi.org/10.1016/S2213-8587(14)70169-X.CrossRefPubMed

41.

Lim DS, Fleseriu M. The role of combination medical therapy in the treatment of acromegaly. Pituitary. 2017;20(1):136–48. https://doi.org/10.1007/s11102-016-0737-y.CrossRefPubMed

42.

Christofides EA. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence. 2016;10:1217–25. https://doi.org/10.2147/PPA.S102302.CrossRefPubMedPubMedCentral

43.

Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83(3–4):249–57. https://doi.org/10.1159/000095535.CrossRefPubMed

44.

Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332. https://doi.org/10.1210/er.2018-00115.CrossRefPubMed

45.

Yedinak CG, Fleseriu M. Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study. Endocrine. 2014;46(3):585–93. https://doi.org/10.1007/s12020-013-0106-9.CrossRefPubMed

46.

Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010;70(13):1745–69. https://doi.org/10.2165/11204510-000000000-00000.CrossRefPubMed

47.

Burness CB, Dhillon S, Keam SJ. Lanreotide autogel((R)): a review of its use in the treatment of patients with acromegaly. Drugs. 2014;74(14):1673–91. https://doi.org/10.1007/s40265-014-0283-8.CrossRefPubMed

48.

Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–8. https://doi.org/10.1007/s11102-017-0791-0.CrossRefPubMed

49.

Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129–35. https://doi.org/10.1007/s11102-016-0753-y.CrossRefPubMed

50.

Lesen E, Granfeldt D, Houchard A, Dinet J, Berthon A, Olsson DS, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;176(2):203–12. https://doi.org/10.1530/EJE-16-0623.CrossRefPubMed

51.

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, et al. Acromegaly at diagnosis in 3173 patients from the Liege acromegaly survey (LAS) database. Endocr Relat Cancer. 2017;24(10):505–18. https://doi.org/10.1530/ERC-17-0253.CrossRefPubMedPubMedCentral

52.

Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20(1):46–62. https://doi.org/10.1007/s11102-017-0797-7.CrossRefPubMed

53.

Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol. 2016;175(5):443–53. https://doi.org/10.1530/EJE-16-0562.CrossRefPubMed

54.

Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M, et al. Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol. 2014;80(5):726–34. https://doi.org/10.1111/cen.12356.CrossRef

55.

Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3132–40. https://doi.org/10.1210/jcem.85.9.6782.CrossRefPubMed

56.

Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Investig. 2002;25(11):971–6. https://doi.org/10.1007/BF03344070.CrossRef

57.

Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol. 2003;58(2):169–76.CrossRef

58.

Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743–7. https://doi.org/10.1210/jc.2006-2547.CrossRefPubMed

59.

Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007;92(2):476–82. https://doi.org/10.1210/jc.2006-1587.CrossRefPubMed

60.

Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7):2639–46. https://doi.org/10.1210/jc.2008-0299.CrossRefPubMed

61.

De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, et al. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary. 2008;11(1):13–20. https://doi.org/10.1007/s11102-007-0062-6.CrossRefPubMed

62.

Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56. https://doi.org/10.1210/jc.2009-0941.CrossRefPubMed

63.

Bogazzi F, Lombardi M, Strata E, Aquaro G, Lombardi M, Urbani C, et al. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance. J Endocrinol Investig. 2010;33(2):103–8. https://doi.org/10.1007/BF03346562.CrossRef

64.

Comunello A, Dassie F, Martini C, De Carlo E, Mioni R, Battocchio M, et al. Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. Pituitary. 2015;18(4):525–34. https://doi.org/10.1007/s11102-014-0605-6.CrossRefPubMed

65.

Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. 2017;55(3):872–84. https://doi.org/10.1007/s12020-016-0995-5.CrossRefPubMed

66.

Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol. 2011;75(2):220–5. https://doi.org/10.1111/j.1365-2265.2011.04019.x.CrossRef

67.

Akdeniz B, Gedik A, Turan O, Ozpelit E, Ikiz AO, Itil O, et al. Evaluation of left ventricular diastolic function according to new criteria and determinants in acromegaly. Int Heart J. 2012;53(5):299–305.CrossRefPubMed

68.

Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–50. https://doi.org/10.1210/jc.2012-3072.CrossRefPubMed

69.

Kuhn E, Maione L, Bouchachi A, Roziere M, Salenave S, Brailly-Tabard S, et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol. 2015;173(5):693–702. https://doi.org/10.1530/EJE-15-0500.CrossRefPubMedPubMedCentral

70.

dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015;100(12):4447–55. https://doi.org/10.1210/jc.2015-2675.CrossRefPubMed

71.

Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, Said Q, et al. The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord. 2017;17(1):15. https://doi.org/10.1186/s12902-017-0166-6.CrossRefPubMedPubMedCentral

72.

Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89(1):71–5. https://doi.org/10.1210/jc.2003-030849.CrossRefPubMed

73.

van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Hormon IGF Res. 2006;16(2):101–7. https://doi.org/10.1016/j.ghir.2006.02.002.CrossRef

74.

Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003;88(7):3196–201. https://doi.org/10.1210/jc.2002-021099.CrossRefPubMed

75.

Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13(1):51–6.CrossRefPubMed

76.

Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E, et al. Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol. 2005;104(2):197–203. https://doi.org/10.1016/j.ijcard.2004.12.010.CrossRefPubMed

77.

Warszawski L, Kasuki L, Sa R, Dos Santos Silva CM, Volschan I, Gottlieb I, et al. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naive acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary. 2016;19(6):582–9. https://doi.org/10.1007/s11102-016-0749-7.CrossRefPubMed

78.

Unubol M, Eryilmaz U, Guney E, Ture M, Akgullu C. QT dispersion in patients with acromegaly. Endocrine. 2013;43(2):419–23. https://doi.org/10.1007/s12020-012-9828-3.CrossRefPubMed

79.

Fatti LM, Scacchi M, Lavezzi E, Pecori Giraldi F, De Martin M, Toja P, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol. 2006;65(5):626–30. https://doi.org/10.1111/j.1365-2265.2006.02639.x.CrossRef

80.

Orosz A, Csajbok E, Czekus C, Gavaller H, Magony S, Valkusz Z, et al. Increased short-term beat-to-beat variability of QT interval in patients with acromegaly. PLoS One. 2015;10(4):e0125639. https://doi.org/10.1371/journal.pone.0125639.CrossRefPubMedPubMedCentral

81.

Ragonese M, Alibrandi A, Di Bella G, Salamone I, Puglisi S, Cotta OR, et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine. 2014;47(1):206–12. https://doi.org/10.1007/s12020-013-0115-8.CrossRefPubMed

82.

Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92(11):4271–7. https://doi.org/10.1210/jc.2007-1213.CrossRefPubMed

83.

Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997–4004. https://doi.org/10.1210/jc.2016-1937.CrossRefPubMed

84.

Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154(3):467–77. https://doi.org/10.1530/eje.1.02112.CrossRefPubMed

85.

Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol. 2008;69(4):613–20. https://doi.org/10.1111/j.1365-2265.2008.03258.x.CrossRef

86.

Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol. 2014;81(4):573–81. https://doi.org/10.1111/cen.12455.CrossRef

87.

Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism. 1990;39(2):133–7.CrossRefPubMed

88.

Muniyappa R, Walsh MF, Rangi JS, Zayas RM, Standley PR, Ram JL, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61(9):925–31.CrossRefPubMed

89.

Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45(2):598–604.CrossRefPubMed

90.

Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648–56. https://doi.org/10.1210/jc.2009-2570.CrossRefPubMed

91.

Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972–8. https://doi.org/10.1210/jc.2004-2009.CrossRefPubMed

92.

Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. 2012;15(1):50–8. https://doi.org/10.1007/s11102-011-0318-z.CrossRefPubMed

93.

Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673–80. https://doi.org/10.1210/jc.2006-1578.CrossRefPubMed

94.

Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo S, De Marinis L, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Investig. 2014;37(10):1017–30. https://doi.org/10.1007/s40618-014-0146-x.CrossRef

95.

Samson SL. Management of Hyperglycemia in patients with acromegaly treated with Pasireotide LAR. Drugs. 2016;76(13):1235–43. https://doi.org/10.1007/s40265-016-0615-y.CrossRefPubMed

96.

Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–8. https://doi.org/10.1210/jc.2008-2332.CrossRefPubMed

97.

Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, et al. Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2018;103:2089–99. https://doi.org/10.1210/jc.2017-02566.CrossRef

98.

Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91. https://doi.org/10.1210/jc.2005-0331.CrossRefPubMed

99.

Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res. 2016;48(5):299–305. https://doi.org/10.1055/s-0035-1569277.CrossRefPubMed

100.

Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14(3):284–94. https://doi.org/10.1007/s11102-011-0310-7.CrossRefPubMedPubMedCentral

101.

Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab. 1998;83(6):2121–5. https://doi.org/10.1210/jcem.83.6.4865.CrossRefPubMed

102.

Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol. 1999;51(5):611–8.CrossRef

103.

Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148(1):31–8.CrossRefPubMed

104.

Claessen KM, Ramautar SR, Pereira AM, Romijn JA, Kroon HM, Kloppenburg M, et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary. 2014;17(1):44–52. https://doi.org/10.1007/s11102-013-0464-6.CrossRefPubMed

105.

Claessen KM, Ramautar SR, Pereira AM, Smit JW, Roelfsema F, Romijn JA, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235–44. https://doi.org/10.1530/EJE-12-0147.CrossRefPubMed

106.

Claessen KM, Mazziotti G, Biermasz NR, Giustina A. Bone and joint disorders in acromegaly. Neuroendocrinology. 2016;103(1):86–95. https://doi.org/10.1159/000375450.CrossRefPubMed

107.

Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100(2):384–94. https://doi.org/10.1210/jc.2014-2937.CrossRefPubMed

108.

Mazziotti G, Frara S, Giustina A. Pituitary diseases and bone. Endocr Rev. 2018;39(4):440–88. https://doi.org/10.1210/er.2018-00005.CrossRefPubMed

109.

Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837–44. https://doi.org/10.1359/JBMR.050603.CrossRefPubMed

110.

Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.CrossRefPubMedPubMedCentral

111.

Godang K, Olarescu NC, Bollerslev J, Heck A. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol. 2016;175(2):155–64. https://doi.org/10.1530/EJE-16-0340.CrossRefPubMed

112.

Tagliafico A, Resmini E, Nizzo R, Bianchi F, Minuto F, Ferone D, et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J Clin Endocrinol Metab. 2008;93(3):905–9. https://doi.org/10.1210/jc.2007-1719.CrossRefPubMed

113.

Resmini E, Tagliafico A, Nizzo R, Bianchi F, Minuto F, Derchi L, et al. Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. Clin Endocrinol. 2009;71(2):220–5. https://doi.org/10.1111/j.1365-2265.2008.03468.x.CrossRef

114.

Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Investig. 2000;23(8):515–9. https://doi.org/10.1007/BF03343767.CrossRef

115.

Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J. Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med. 2001;164(5):852–7. https://doi.org/10.1164/ajrccm.164.5.2005059.CrossRefPubMed

116.

Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533–40. https://doi.org/10.1530/EJE-08-0442.CrossRefPubMed

117.

Akkoyunlu ME, Ilhan MM, Bayram M, Tasan E, Yakar F, Ozcelik HK, et al. Does hormonal control obviate positive airway pressure therapy in acromegaly with sleep-disordered breathing? Respir Med. 2013;107(11):1803–9. https://doi.org/10.1016/j.rmed.2013.08.043.CrossRefPubMed

118.

Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol. 2006;155(6):831–7. https://doi.org/10.1530/eje.1.02292.CrossRefPubMed

119.

Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol. 2008;158(3):305–10. https://doi.org/10.1530/EJE-07-0697.CrossRefPubMed

120.

T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol. 2007;157(4):411–7. https://doi.org/10.1530/EJE-07-0356.CrossRefPubMed

121.

Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol. 2017;86(6):806–15. https://doi.org/10.1111/cen.13331.CrossRef

122.

Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853–9. https://doi.org/10.1210/jc.2008-0669.CrossRefPubMed

123.

Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol. 2007;67(3):358–62. https://doi.org/10.1111/j.1365-2265.2007.02891.x.CrossRef

124.

Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf). 2005;63(1):103–10. https://doi.org/10.1111/j.1365-2265.2005.02307.x.CrossRef

125.

Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by acromegaly quality of life (AcroQoL) questionnaire. Endocrine. 2015;49(3):774–82. https://doi.org/10.1007/s12020-014-0521-6.CrossRefPubMed

126.

Webb SM, Crespo I, Santos A, Resmini E, Aulinas A, Valassi E. MANAGEMENT OF ENDOCRINE DISEASE: quality of life tools for the management of pituitary disease. Eur J Endocrinol. 2017;177(1):R13–26. https://doi.org/10.1530/EJE-17-0041.CrossRefPubMed

127.

Imran SA, Tiemensma J, Kaiser SM, Vallis M, Doucette S, Abidi E, et al. Morphometric changes correlate with poor psychological outcomes in patients with acromegaly. Eur J Endocrinol. 2016;174(1):41–50. https://doi.org/10.1530/EJE-15-0888.CrossRefPubMed

128.

Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90(5):2731–9. https://doi.org/10.1210/jc.2004-2297.CrossRefPubMed

129.

Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C. Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. Front Endocrinol (Lausanne). 2014;5:229. https://doi.org/10.3389/fendo.2014.00229.

130.

Tiemensma J, Pereira AM, Romijn JA, Broadbent E, Biermasz NR, Kaptein AA. Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. Eur J Endocrinol. 2015;172(5):583–93. https://doi.org/10.1530/EJE-14-0996.CrossRefPubMed

131.

Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab. 2011;96(11):3550–8. https://doi.org/10.1210/jc.2011-1645.CrossRefPubMed

132.

Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114(3):349–56. https://doi.org/10.1172/JCI19933.CrossRefPubMedPubMedCentral

133.

Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol. 2009;160(4):543–8. https://doi.org/10.1530/EJE-08-0822.CrossRefPubMed

134.

Neggers SJ, Kopchick JJ, Jorgensen JO, van der Lely AJ. Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol. 2011;164(1):11–6. https://doi.org/10.1530/EJE-10-0969.CrossRefPubMed

135.

Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924–933. https://doi.org/10.3275/6723 10.1007/BF03345774.

136.

Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P. Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 2014;17(6):557–63. https://doi.org/10.1007/s11102-013-0544-7.CrossRefPubMed

137.

van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325–33. https://doi.org/10.1530/EJE-10-0867.CrossRefPubMed

138.

Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab. 2011;96(8):2405–13. https://doi.org/10.1210/jc.2011-0654.CrossRefPubMed

139.

Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90(10):5627–31. https://doi.org/10.1210/jc.2005-0531.CrossRefPubMed

140.

De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10(3):227–32. https://doi.org/10.1007/s11102-007-0037-7.CrossRefPubMed

141.

Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169(1):99–108. https://doi.org/10.1530/EJE-13-0032.CrossRefPubMed

142.

Brue T, Castinetti F. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis. 2016;11(1):135. https://doi.org/10.1186/s13023-016-0516-x.CrossRefPubMedPubMedCentral

143.

Mercado M, Gonzalez B, Vargas G, Ramirez C. de los Monteros AL, Sosa E et al. successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12):4438–46. https://doi.org/10.1210/jc.2014-2670.CrossRefPubMed

Titel: Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly
verfasst von: Federico Gatto
Claudia Campana
Francesco Cocchiara
Giuliana Corica
Manuela Albertelli
Mara Boschetti
Gianluigi Zona
Diego Criminelli
Massimo Giusti
Diego Ferone
Publikationsdatum: 24.07.2019
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2019
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-019-09506-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Risk of vertebral fractures in hypoparathyroidism

Neuroendocrinological mechanisms underlying impulsive and compulsive behaviors in obesity: a narrative review of fMRI studies

Vitamin D in physiological and pathological aging: Lesson from centenarians

Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease

Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies

Calcium citrate: from biochemistry and physiology to clinical applications

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin